10-K: INVO Fertility Details Capital Stock Structure

INVO Fertility, Inc. outlines its authorized capital stock, including common and various series of preferred stock, detailing their rights and conversion terms.

Summary

• The filing details INVO Fertility, Inc.'s capital stock structure, including authorized shares of common stock and preferred stock (Series A, B, C-1, C-2, and D).
• It specifies the par value, authorized quantities, and rights associated with each class of stock, including voting rights, dividend entitlements, and liquidation preferences.
• Details are provided on the conversion prices and terms for the convertible preferred stock series, along with any limitations on beneficial ownership upon conversion.
• The document also covers provisions related to stock options, restricted stock units, unit purchase options, and warrants outstanding as of December 31, 2025.
• Furthermore, it discusses anti-takeover provisions in the company's articles of incorporation, bylaws, and Nevada state law, designed to deter hostile takeovers and promote management stability.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant accumulated losses, ongoing cash burn, and Nasdaq non-compliance, despite strategic acquisitions and a growing market.

Positives

• The company has a clear structure for its capital stock, with defined rights and preferences for different classes of shares.
• The INVOcell device has received FDA clearance for marketing and use, with an expanded 5-day incubation period clearance demonstrating improved patient outcomes.
• The company has a strategy to acquire profitable fertility clinics, which has already led to significant revenue growth.
• The company is ISO 13485:2016 certified for manufacturing, indicating adherence to quality management standards.

Negatives

• The company has incurred substantial accumulated net losses since inception ($91.4 million as of December 31, 2025), raising substantial doubt about its ability to continue as a going concern.
• The company has substantial secured indebtedness outstanding, and failure to service this debt could lead to seizure and liquidation of assets.
• The company's current cash position is not expected to be sufficient to fund operations and service debt for the next 12 months, requiring additional capital which may not be available on acceptable terms.
• Future fundraising efforts may be dilutive to existing stockholders and could impose restrictive covenants limiting operational flexibility.
• The company has identified material weaknesses in its internal control over financial reporting, specifically related to segregation of duties and accounting resources, which could impact the accuracy and timeliness of financial reporting.

Risks

• The company has an accumulated net loss of $91.4 million since inception, raising substantial doubt about its ability to continue as a going concern.
• Substantial secured indebtedness outstanding could lead to asset seizure if debt obligations are not met.
• Current cash position is insufficient to fund operations and service debt for the next 12 months, and additional capital may not be available on acceptable terms.
• Future fundraising may be dilutive and impose restrictive covenants.
• The fertility and ART services industry is highly competitive, with potential erosion of market share from new providers or technologies.
• Growth strategy relies on successful acquisition and integration of fertility clinics, with risks of failing to realize synergies or encountering unforeseen liabilities.
• Dependence on key executives and personnel; their loss could materially harm operations.
• Joint venture partners may fail to perform obligations or seek to terminate agreements.
• Significant litigation exposure from medical malpractice, errors in handling reproductive materials, and product liability claims, potentially exceeding insurance coverage.
• Reliance on a single third-party manufacturer for INVOcell production poses supply disruption or quality failure risks.
• Intellectual property rights may be challenged or circumvented, leading to costly infringement claims.
• Evolving laws on abortion and embryo personhood could restrict IVF services.
• Noncompliance with extensive federal and state regulations for clinic operators and medical device manufacturers could result in penalties or cessation of operations.
• FDA clearance processes are expensive and uncertain; failure to obtain or maintain clearances could impact commercialization.
• Payor consolidation and managed care trends could lead to pricing pressure and reduced demand for services.
• Cybersecurity threats or data breaches involving patient health information could lead to HIPAA liability and operational disruption.
• Restrictive covenants in secured debt instruments limit operational and financial flexibility.
• Thinly traded and highly volatile common stock may not reflect true value, and there's no assurance of an active trading market.
• Former shell company status may restrict resale of restricted securities under Rule 144.
• Directors have broad authority to issue preferred or additional common stock, potentially diluting existing holders.
• The company has never paid dividends and does not expect to in the foreseeable future.
• Failure to comply with Nasdaq listing standards could lead to delisting, reducing liquidity and investor confidence.
• Global economic volatility, inflation, rising interest rates, and geopolitical instability could affect capital access and patient demand.
• Changes in U.S. tariff and trade policy could increase operating costs.
• Economic downturns may reduce consumer spending on fertility treatments.
• Reduced disclosure requirements as a Smaller Reporting Company may make stock less attractive to some investors.
• Material weaknesses in internal control over financial reporting could lead to inaccurate or untimely financial reporting.
• Failure to attract qualified personnel could hinder business expansion.
• Changes in laws regarding abortion could affect embryo handling and fertility procedures.
• The company's operations are subject to significant domestic and international governmental regulation.
• The FDA regulatory review process is expensive, time-consuming, and uncertain.
• Changes in healthcare industry pricing and profitability regulations could impact the company.
• Recent economic trends, including inflation and supply chain constraints, could adversely affect financial performance.
• The trading price of common stock is highly volatile, potentially leading to substantial losses for purchasers.
• Securities class action litigation could substantially harm the company's business.

Future Outlook

The company plans to grow its fertility operations organically and through acquisitions of profitable fertility clinics. It also intends to continue growing its INVOcell business and seek out new fertility-focused technologies. The company anticipates benefiting from positive trends in the global ART market, including an underserved patient population, increasing infertility rates, and growing acceptance of fertility treatments.

Management Comments

• Our acquisition strategy focuses on US-based, profitable fertility clinics.
• The acquisition of profitable fertility clinics complements our efforts to build new INVO Centers, and we expect to continue this strategy to accelerate overall growth.
• Our renewed focus on our core fertility operations best serves our growth objectives.

Industry Context

StockSavvy.ai notes that the global ART marketplace is a large and growing multi-billion-dollar industry, driven by increasing infertility rates and greater patient awareness. The industry remains capacity-constrained, creating opportunities for companies like INVO Fertility to expand access to care. The company's strategy of acquiring existing clinics and developing new ones, alongside its INVOcell technology, positions it to capitalize on these market dynamics.

Corporate Governance

Legal Proceedings

• Dr. Elizabeth Pritts and the Elizabeth Pritts Revocable Living Trust filed a complaint alleging breach of contract, breach of good faith and fair dealing, tortious interference, and unjust enrichment related to the Wisconsin Fertility Institute (WFI) acquisition documents.
• A settlement agreement was reached, with Wood Violet agreeing to pay Dr. Pritts $6,000,000 in full and final settlement, with scheduled payments through December 31, 2026. A consent judgment will be entered upon breach of the settlement agreement.

Related Party Transactions

• The company has outstanding demand promissory notes and convertible notes with JAG Multi Investments LLC (JAG), a company in which the Chief Business Officer is a beneficiary.
• The company received $200,000 in demand promissory notes from its Chief Executive Officer and an entity controlled by its Chief Business Officer in Q4 2022.

Stakeholder Impact

• Shareholders may experience dilution from future fundraising efforts and potential issuance of preferred stock or additional common stock.
• The company's ability to continue as a going concern raises concerns for all stakeholders, particularly stockholders who could lose their investment.
• Failure to regain Nasdaq compliance could negatively impact investor confidence and the liquidity of shares for stockholders.
• The company's reliance on debt financing and potential covenant defaults could impact its ability to operate and generate returns for shareholders.

Next Steps

• Regain compliance with Nasdaq listing standards by filing required reports.
• Continue to grow clinic revenue organically and pursue additional fertility clinic acquisitions.
• Seek additional funding through debt and/or equity financing to meet liquidity needs and execute business strategy.
• Monetize minority stake in NAYA Therapeutics in the future.

Key Dates

Recommendation

While INVO Fertility is operating in a growing market and has made strategic acquisitions, the company faces significant financial challenges, including substantial accumulated losses and a precarious cash position. The ongoing Nasdaq non-compliance further adds to the risk profile. The company's ability to secure additional financing and successfully execute its growth strategy without further dilution or financial distress is critical. Therefore, a 'hold' recommendation is appropriate, pending clearer signs of financial stability and regulatory compliance.

Keywords

INVO Fertility, Capital Stock, Common Stock, Preferred Stock, Series A Preferred, Series B Preferred, Series C-1 Preferred, Series C-2 Preferred, Series D Preferred, Convertible Stock, Warrants, Stock Options, SEC Filing, 10-K, Corporate Governance, Articles of Incorporation, Bylaws, Nevada Anti-Takeover Provisions